Amphetamine Stimulant Prodrug denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for amphetamine stimulant prodrug are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for This Drug

UnitedHealthcare places amphetamine-based stimulant prodrugs on its prior authorization (PA) list as part of standard formulary management for this drug class. A prior-authorization-required denial means the prescription was dispensed or requested without an approved PA on file — either because the PA was never submitted, was submitted but not approved before the prescription was filled, or because a previously approved PA has expired.

This denial type is primarily administrative in nature, but it still requires a formal response through UHC's PA or appeal process to secure coverage.

## Why This Denial Is Appealable

If the clinical criteria for medical necessity are met, UHC is required to approve the prior authorization. If an initial PA was submitted and denied, that denial is a formal adverse benefit determination subject to the full internal appeal and external review rights under ACA §2719 and ERISA §503. If no PA was submitted, the path forward is a retroactive PA request (for already-dispensed prescriptions) or a prospective PA submission.

## Federal Appeal Framework

• Retroactive PA / internal appeal: For already-dispensed claims, submit a retroactive PA request with supporting documentation. If denied, this triggers formal internal appeal rights.
• Internal appeal (ACA §2719 / ERISA §503): Submit within the deadline on the denial notice (typically 180 days for ERISA plans).
• External review: After exhausting internal appeals, you have approximately four months from the final internal denial to request independent external review. Expedited PA review (typically 72 hours) is available when standard timelines would seriously jeopardize health or function.

## Concrete Appeal Steps and Timeline

1. Determine the PA status — was a PA ever submitted? If yes, was it approved, denied, or still pending? 2. Obtain UHC's PA criteria for this drug from the Clinical Coverage Policy. 3. If no PA was submitted: Submit a prospective PA (or retroactive PA for past fills) with full clinical documentation. 4. If the PA was denied: Treat that denial as the adverse benefit determination and proceed through the formal internal appeal process. 5. Escalate to external review if the internal appeal is denied, within the four-month window.

## Documentation to Gather

• Diagnosis documentation: Chart notes and evaluations confirming the diagnosis and its severity.
• Prior treatment history: Medications previously tried, with dates, documented outcomes, and reasons for discontinuation — addressing any step-therapy requirements within the PA criteria.
• Prescriber medical-necessity letter: Should be structured around UHC's specific PA criteria, addressing each requirement with documented chart facts.
• Prescriber contact information: UHC's PA process may require a peer-to-peer review between the prescriber and UHC's medical director — confirm availability.

## Criteria-Mapping Structure

| UHC Prior-Auth Criterion | Patient Evidence | |---|---| | Confirmed diagnosis requirement | Cite chart notes and evaluation dates | | Prior therapy / step-therapy requirement | Document each prior medication trial with dates and outcomes | | Severity or functional impairment criteria | Cite specific chart documentation | | Any additional PA criteria | Address each with prescriber letter and chart support |

Requesting a peer-to-peer review between the prescriber and UHC's medical director — available during the PA and appeal stages — resolves a substantial proportion of PA denials before they require formal external review.